# Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

> **NCT04402580** · PHASE2 · TERMINATED · sponsor: **Istituto Giannina Gaslini** · enrollment: 30 (actual)

## Conditions studied

- Nephrotic Syndrome Steroid-Dependent

## Interventions

- **DRUG:** Rituximab Biosimilar
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT04402580
- **Lead sponsor:** Istituto Giannina Gaslini
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-01
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** due to unexpectedly high rate of relapse in the active comparator arm.
- **Last updated:** 2020-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402580, "Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04402580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*